findmyKOL

Kenneth Kalunian, MD

Enriched profile

Professor of Medicine and Rheumatology; Wolfe Family Director, UC San Diego Lupus Center; Vice Chief of Clinical Research · University of California, San Diego

ORCIDNPI
Region🇺🇸 San Diego, CA · West · United StatesSpecialtyRheumatologyFocusSystemic Lupus Erythematosus Research+4
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2025Online presenceverified 2026Payments2021–2025NIH funding2001–2010

Kenneth Kalunian is Professor of Medicine and Rheumatology; Wolfe Family Director, UC San Diego Lupus Center; Vice Chief of Clinical Research at University of California, San Diego. OpenAlex indexes 379 publications with 26,876 citations (h-index 75); ClinicalTrials.gov lists 7 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Rheumatology profiles in the findmyKOL directory.

Data verified 14 Aug 2026

Overview

Updated 27 Aug 2026

Kenneth Kalunian, MD, is Professor of Medicine and Rheumatology at University of California, San Diego, School of Medicine. The public record shows 379 publications with 26,876 citations (h-index 75), centered on Systemic Lupus Erythematosus Research, Rheumatoid Arthritis Research and Therapies, Monoclonal and Polyclonal Antibodies Research. It also documents an investigator role on 7 registered clinical trials, industry payments reported by 27 companies, 2 NIH-funded awards (2001–2010).

  • Most recent indexed publication: 2025 · The Journal of experimental medicine
  • Top research focus: Systemic Lupus Erythematosus Research
  • 7 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 27 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Lupus (SLE)4 trialsOsteoarthritis3 trialsErythema3 trialsST Elevation Myocardial Infarction2 trialsGlomerular Disease2 trialsNephritis2 trialsMultiple SclerosisRheumatoid Arthritis

Research focus

OpenAlex concept fingerprint
Systemic Lupus Erythematosus ResearchRheumatoid Arthritis Research and TherapiesMonoclonal and Polyclonal Antibodies ResearchMultiple Sclerosis Research StudiesLiver Diseases and Immunity

Drugs & molecules

across trials, industry payments and publications
Saphnelogeneric · AnifrolumabClinical trialsIndustry payments9Publications2Benlystageneric · BelimumabClinical trialsIndustry payments8PublicationsLupkynisgeneric · VoclosporinClinical trialsIndustry payments7Publications

Works with

trial sponsors and companies reporting payments
Aurinia Pharma U.S., Inc.Clinical trialsIndustry payments17Pfizer Inc.Clinical trialsIndustry payments17AstraZeneca Pharmaceuticals LPClinical trialsIndustry payments14

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
379publications

Distinct works indexed by OpenAlex, matched via ORCID; 4 in PubMed.

26,876citations

Total citations across indexed works.

75h-index

Hirsch index (OpenAlex). i10-index 177.

Clinical & industry

trials, payments and federal funding
7clinical trials

Investigator role on registered studies.

View trials
27companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
2NIH grants · 2001–2010

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 7 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

27 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    42.4%
    TNF inhibitor17.4%
    Enbrel Sureclick56%Humira16%Humira(Cf) Pen16%Enbrel12%
    Part D<11 patients
    Folate Analog Metabolic Inhibitor6.8%
    Methotrexate100%
    Part D<11 patients
  • Antiparasitic

    26.6%
    Antimalarial26.6%
    Hydroxychloroquine Sulfate100%
    Part D41 patients
  • Metabolism & gastrointestinal

    13.2%
    Corticosteroid11.6%
    Prednisone100%
    Part D18 patients
    Insulin Analog1.6%
    Toujeo Max Solostar100%
    Part D<11 patients
4 more therapeutic areas behind the reveal.Reveal →
Where care is delivered (Part B)16.8% facility · 83.2% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 27 Aug 2026

2 NIH research awards on record, funded 20012010 per NIH RePORTER. The latest:

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 27 Aug 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/kenneth-kalunian-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com
  • LinkedIn

    linkedin.com/in/kenneth-kalunian-35a5a9291

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com
  • ResearchGate

    researchgate.net/profile/Kenneth-Kalunian

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net
2 more verified accounts behind the reveal.Reveal →

Mentions by others

where others cite or feature them
  • Other

    lupustherapeutics.org/team-member/kenneth-kalunian-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →lupustherapeutics.org
  • Other

    rheumnow.live/b/sp/ken-kalunian-82

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →rheumnow.live

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments
  • Chair

    Steering Committee, Lupus Research Alliance Clinical Investigator Network (LuCIN)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →sliccgroup.org
  • Founder and first director

    Lupus Foundation of America Collective Data Analysis Initiative

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →lupustherapeutics.org
  • Former President

    Southern California Rheumatology Society

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →lupustherapeutics.org
2 more roles behind the reveal.Reveal →

Secondary affiliations

appointments beyond the home institution
  • Co-Director

    UC San Diego Center for Innovative Therapy

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →sliccgroup.org
  • Director

    UC San Diego Lupus Center of Excellence / Lupus Clinical Trials Consortium

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →sliccgroup.org
  • Director

    UC San Diego Osteoarthritis Center

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →hcplive.com
3 more affiliations behind the reveal.Reveal →

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.